Compare Rex Fang & Innovation Equity Premium Income ETF (FEPI) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rex Fang & Innovation Equity Premium Income ETF vs Travere Therapeutics Inc. Common Stock — how do they compare? Rex Fang & Innovation Equity Premium Income ETF trades at $41.82 (market cap $753.07M), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $5.02B). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 6.7× Rex Fang & Innovation Equity Premium Income ETF's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, Rex Fang & Innovation Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Rex Fang & Innovation Equity Premium Income ETF for 57 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| FEPI | TVTX | |
|---|---|---|
Market Cap | $753.07M | $5.02B |
Volume | 329,956 | 2,060,842 |
Sector | Income / Options Overlay | Health |
52-Week High | $49.54 | $67.52 |
52-Week Low | $37.98 | $26.79 |
Typical Hold Time | 57 Days | 0 Days |
Enterprise Value | — | $5.15B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FEPI (REX FANG & Innovation Equity Premium Income ETF) trades at $43.28, showing minimal daily movement with a 0.14% gain. The ETF employs a covered call strategy on AI and mega-cap tech stocks, generating substantial weekly dividends averaging $0.20-0.21 per share. Technical indicators show a bullish trend with strong moving average support, while oscillators remain neutral. Recent news highlights FEPI's 25% yield but notes underperformance compared to peers in total returns.
FEPI offers high income potential through its covered call strategy but faces capped upside and concentrated tech exposure risks. The ETF's performance depends heavily on AI sector volatility and options pricing efficiency. While attractive for income-focused investors, total return potential may lag broader market indices during strong bull markets.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Rex Fang & Innovation Equity Premium Income ETF
FEPI provides exposure to top innovation stocks while generating monthly income. It uses a covered call strategy on high-volatility tech stocks to capture option premiums for investors.
Read more on FEPI →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
